Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Eli Lilly Breaks New Ground In Crohn's Disease Treatment

Eli Lilly Breaks New Ground In Crohn's Disease Treatment

FinvizFinviz2026/02/20 12:27
By:Finviz

Eli Lilly and Co. (NYSE:LLY) on Thursday released promising long-term data regarding its treatment for Crohn’s disease.

This news comes as the company reported that more than 90% of patients maintained steroid-free remission for three years with Omvoh (mirikizumab-mrkz).

The latest data from Eli Lilly’s Phase 3 VIVID-2 study revealed clinical remission of 92.4%, and Corticosteroid-free clinical remission of 91.2%.

Additional data presented from the Phase 3 VIVID-1 (Crohn’s disease) and LUCENT-3 (Ulcerative colitis UC) trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease (IBD).

In VIVID-1, Omvoh reduced Crohn’s disease-related hospitalizations and/or surgeries by nearly half versus placebo in the first 12 weeks (incidence rate: 16.9 vs. 30.9 per 100 patient-years), and by nearly 70% during weeks 12 to 52 (4.5 vs. 14.0).

In LUCENT-3, one UC-related hospitalization and no UC-related surgeries were reported by patients treated with Omvoh during the three-year long-term extension.

In the context of this data, Omvoh stands out as the only IL-23p19 inhibitor to demonstrate durable efficacy over extended periods, with significant improvements in bowel urgency and overall disease control.

This positions Eli Lilly favorably in the competitive landscape of treatments for inflammatory bowel disease.

In January 2025, the U.S Food and Drug Administration (FDA) approved Omvoh for moderately to severely active Crohn’s disease in adults.

Technical Analysis

Currently, the stock is trading 1.7% below its 20-day simple moving average (SMA) and 4.3% above its 100-day SMA, indicating a mixed short-term trend but longer-term strength.

Over the past 12 months, shares have increased 17.19% and are currently positioned closer to their 52-week highs, reflecting a strong upward trajectory.

The RSI is at 46.60, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at -6.7903, below its signal line at -4.8820, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum.

  • Key Resistance: $1088.50
  • Key Support: $1012.50

Sector Performance

Eli Lilly is currently outperforming its sector, with a slight gain of 0.02% compared to the Healthcare sector’s flat performance of 0.00%.

The Healthcare sector is ranked 5 out of 11 sectors, indicating a mid-tier performance, and has seen a slight decline of 0.63% over the past 30 days.

Despite the recent stability, the sector has shown a modest increase of 1.29% over the past 90 days, suggesting a potential recovery trend.

Eli Lilly’s positive news regarding Omvoh may further bolster its position within the sector as it continues to innovate in treatment options.

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Eli Lilly, highlighting its strengths and weaknesses compared to the broader market:

  • Value Rank: 3.69 — Stock is trading at a premium compared to peers.
  • Quality Rank: 94.09 — Indicates a strong balance sheet and operational efficiency.
  • Momentum Rank: 82.03 — Stock is outperforming the broader market.

The Verdict: Eli Lilly’s Benzinga Edge signal reveals a strong position in the market, particularly with its momentum score indicating robust performance. However, the low value rank suggests that investors should be cautious about potential overvaluation as the stock continues to rise.

LLY Price Action: Eli Lilly shares were up 0.02% at $1023.45 during premarket trading on Friday, according to Benzinga Pro data.

Image via Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.

Goldman Sachs' head of trading believes the current US stock market is repeating the scenario of late 2018, with monetary tightening and equity market pressure. The Goldman Sachs Financial Conditions Index has tightened by about 8 points in two weeks, reaching the highest level in a year. The selloff has broadened from tech stocks to defensive sectors. Gold and equities are declining simultaneously, possibly indicating investors are selling assets to raise cash, making gold a key indicator for observing liquidity stress.

华尔街见闻•2026/11/21 05:31
The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.

Goldman Sachs Trader “Revisits the 2018 Playbook”: Still Clearly Remembers “On December 24th, Clients Asked Why the Market Dropped So Much—And I Had No Idea”

Brian Garrett pointed out that the current adjustment in the US stock market is similar to the sharp decline in Q4 2018: the S&P 500 has already experienced 42% of the corresponding drop, and the VIX is approaching its peak just before Christmas. If history repeats itself, the bottom of this cycle may appear in January next year. However, the credit market and Federal Reserve policy have yet to provide clear signals of a bottom.

华尔街见闻•2026/11/21 03:51

Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis

On November 20th, Eastern Time, on its second day of trading, Anthropic's intraday price dropped to a low of $83.05, just 5 cents above the offering price of $83, and finally closed at $88.91, a decline of 8.50%. On the same day, the company's mathematician Levant Alperg announced on his personal website that he and Claude had found a candidate proof for the Riemann hypothesis, which has puzzled the mathematics community for 167 years, and released about 17 million lines of Lean formalized code.

智通财经•2026/11/21 03:21
Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis

As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.

According to Rentrak data, the global box office of "Grand Theft Auto VI" has also surpassed that of "Avengers: Endgame," the highest-grossing film of all time, which has a global box office of approximately $2.94 billion.

智通财经•2026/11/21 02:41
As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.